Management of Epidermal Growth Factor Receptor (EGFR) - Mutated Non-small-cell Lung Cancer (NSCLC)

Genetic Mutations and Molecular Alterations in NSCLC : Implications for Diagnosis and TreatmentПодробнее

Genetic Mutations and Molecular Alterations in NSCLC : Implications for Diagnosis and Treatment

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung CancerПодробнее

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer

Unlocking NSCLC EGFR Gene Mutations Explained!Подробнее

Unlocking NSCLC EGFR Gene Mutations Explained!

Osimertinib: Key Facts for Lung Cancer TreatmentПодробнее

Osimertinib: Key Facts for Lung Cancer Treatment

The Implications of Recent Datasets for the Current and Future Management of NSCLC EGFR MutationsПодробнее

The Implications of Recent Datasets for the Current and Future Management of NSCLC EGFR Mutations

The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung ...Подробнее

The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung ...

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage diseaseПодробнее

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

Osimertinib Tablet Explained: Uses, Dosage, Mechanism, Side Effects & Expert Advice | MediInsightsПодробнее

Osimertinib Tablet Explained: Uses, Dosage, Mechanism, Side Effects & Expert Advice | MediInsights

Interview with Jonathan Goldman, MD: Management of Non-Small Cell Lung Cancer with an EGFR MutationПодробнее

Interview with Jonathan Goldman, MD: Management of Non-Small Cell Lung Cancer with an EGFR Mutation

New FDA-Approved Treatment for EGFRm NSCLC First-line! 🙌 Groundbreaking ApproachПодробнее

New FDA-Approved Treatment for EGFRm NSCLC First-line! 🙌 Groundbreaking Approach

Dr. Jordi Ramon on EGFR-Mutant Lung Cancer: Targeted Therapy & Resistance Strategies | OncoDailyПодробнее

Dr. Jordi Ramon on EGFR-Mutant Lung Cancer: Targeted Therapy & Resistance Strategies | OncoDaily

Management of early stage lung cancer with TKIsПодробнее

Management of early stage lung cancer with TKIs

Management of AEs from amivantamab and lazertinib for EGFR-m NSCLCПодробнее

Management of AEs from amivantamab and lazertinib for EGFR-m NSCLC

First-line treatment of metastatic EGFR-mutated non-small cell lung cancerПодробнее

First-line treatment of metastatic EGFR-mutated non-small cell lung cancer

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLCПодробнее

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationПодробнее

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

CRSF 07th Masterclass: Uncommon EGFR Mutations in Lung Cancer | Dr. Pradeep VentrapatiПодробнее

CRSF 07th Masterclass: Uncommon EGFR Mutations in Lung Cancer | Dr. Pradeep Ventrapati

Evaluating first-line therapies for EGFR-mutated NSCLC in 2024Подробнее

Evaluating first-line therapies for EGFR-mutated NSCLC in 2024

What is oligoprogression? How is it managed in EGFR-mutated metastatic NSCLC while on osimertinib?Подробнее

What is oligoprogression? How is it managed in EGFR-mutated metastatic NSCLC while on osimertinib?

Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community SettingПодробнее

Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting